NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot ...
Mylan to invest an additional $20M in Mapi Pharma in support of continued progress on Phase 3 clinical studies “Mapi Pharma and Mylan share a commitment to improve the lives of MS patients, and I am ...
NESS ZIONA, Israel, March 31, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
PITTSBURGH and NESS ZIONA, Israel, Aug. 7, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development ...
NESS ZIONA, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...
The SIC code for this company is 2834, Pharmaceutical Preparations. There were 29 documents filed with this form. The SEC file number is 0001178913-14-002187. The contact information for this company ...
The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback